Cost-effectiveness of Intensity-modulated Radiotherapy in Oropharyngeal Cancer

Clinical Oncology

Volumn 24, Issue 7, 2012, Pages 532-538

  Yong, J H E ^a,b,c   Beca, J ^a,b,c   O'Sullivan, B ^d   Huang, S H ^d   McGowan, T ^e,f   Warde, P ^b,d,e   Hoch, J S ^a,b,c,g  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b CANCER CARE ONTARIO   (Canada)

^c Canadian Centre for Applied Research in Cancer Control (ARCC)   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f CREDIT VALLEY HOSPITAL   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cost effectiveness analysis; Costs and cost analysis; Head and neck neoplasms; Quality of life; Radiotherapy; Xerostomia

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; COMPARATIVE STUDY; COMPUTER ASSISTED RADIOTHERAPY; COST EFFECTIVENESS ANALYSIS; HIDDEN MARKOV MODEL; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LONG TERM CARE; OROPHARYNX CANCER; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; XEROSTOMIA;

COST-BENEFIT ANALYSIS; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; OROPHARYNGEAL NEOPLASMS; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84864766632     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2012.05.010     Document Type: Article

References (26)

1. Lee N.Y., de Arruda F.F., Puri D.R., et al. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006, 66(4):966-974.
2. Pow E.H., Kwong D.L., McMillan A.S., et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006, 66(4):981-991.
3. Scott-Brown M., Miah A., Harrington K., Nutting C. Evidence-based review: quality of life following head and neck intensity-modulated radiotherapy. Radiother Oncol 2010, 97(2):249-257.
4. Chao K.S., Majhail N., Huang C.J., et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol 2001, 61(3):275-280.
5. Lindberg R. Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 1972, 29(6):1446-1449.
6. O'Sullivan B., Rumble R.B., Warde P. Intensity modulated radiotherapy in the treatment of head and neck cancer. Clin Oncol 2012, 24. 000-000.
7. Ho K.F., Farnell D.J., Routledge J.A., et al. Comparison of patient-reported late treatment toxicity (LENT-SOMA) with quality of life (EORTC QLQ-C30 and QLQ-H&N35) assessment after head and neck radiotherapy. Radiother Oncol 2010, 97(2):270-275.
8. Nutting C.M., Morden J.P., Harrington K.J., et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011, 12(2):127-136.
9. Guidelines for the economic evaluation of health technologies: Canada 2006, Canadian Agency for Drugs and Technologies in Health, Ottawa. 3rd ed.
10. Statistics Canada. Life Tables, Canada, Provinces and Territories, 2000 to 2002. 2006. Report No.: Catalogue no. 84-537-XIE.
11. American Cancer Society. Cancer facts and figures 2012. Available at:; 2012. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf.
12. Bond M., Mealing S., Anderson R., et al. The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model. Health Technol Assess 2009, 13(44):1-330.
13. Nichol M.B., Sengupta N., Globe D.R. Evaluating quality-adjusted life years: estimation of the health utility index (HUI2) from the SF-36. Med Decis Making 2001, 21(2):105-112.
14. Hummel S., Simpson E., Hemingway P., Stevenson M., Rees A. Intensity modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Health Technol Assess 2010, 14(47):1-108. iii-iv.
15. Chen A.M., Farwell D.G., Luu Q., Vazquez E.G., Lau D.H., Purdy J.A. Intensity-modulated radiotherapy is associated with improved global quality of life among long-term survivors of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2012.
16. Pow E.H., Kwong D.L., Sham J.S., Lee V.H., Ng S.C. Can intensity-modulated radiotherapy preserve oral health-related quality of life of nasopharyngeal carcinoma patients?. Int J Radiat Oncol Biol Phys 2012.
17. Yong J.H.E., Beca J., McGowan T., Bremner K.E., Warde P., Hoch J. Cost-effectiveness of intensity-modulated radiotherapy in prostate cancer. Clin Oncol 2012, 24. 000-000.
18. Kam M.K., Leung S.F., Zee B., et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007, 25(31):4873-4879.
19. Konski A., Watkins-Bruner D., Feigenberg S., et al. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys 2006, 66(2):408-415.
20. Wan L.S., Lee T.F., Chien C.Y., Chao P.J., Tsai W.L., Fang F.M. Health-related quality of life in 640 head and neck cancer survivors after radiotherapy using EORTC QLQ-C30 and QLQ-H&N35 questionnaires. BMC Cancer 2011, 11:128.
21. Little M., Schipper M., Feng F.Y., et al. Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands. Int J Radiat Oncol Biol Phys 2011.
22. EuroQol Group. EQ-5D. Available at: mailto:http://www%20euroqol%20org/.
23. Bourhis J., Blanchard P., Maillard E., et al. Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data. J Clin Oncol 2011, 29(18):2590-2597.
24. Sasse A.D., Clark L.G., Sasse E.C., Clark O.A. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. Int J Radiat Oncol Biol Phys 2006, 64(3):784-791.
25. Kesteloot K., Lievens Y., van der Schueren E. Improved management of radiotherapy departments through accurate cost data. Radiother Oncol 2000, 55(3):251-262.
26. Das I.J., Moskvin V., Johnstone P.A. Analysis of treatment planning time among systems and planners for intensity-modulated radiation therapy. J Am Coll Radiol 2009, 6(7):514-517.